Researchers from England examined the seroprevalence, correlates, and characteristics of undetected celiac disease in an adult population in Cambridge.
The team invited individuals (45 to 76 years) from 12 general practices to take part in a health survey that included a bone density measurement.
|EMA positive patients have an increased risk of osteoporosis.|
Between 1990 and 1995, the team tested a total of 7550 participants’ serum samples for antiendomysial antibody (EMA).
The researchers based seroprevalence of undetected celiac disease on EMA positivity.
They evaluated the differences between EMA positive and negative participants using multivariate logistic and linear regression and adjusted for age, sex, social class, and smoking.
The team found that the seroprevalence of undetected celiac disease was 1%
They determined that EMA positive participants were slightly lighter by 2.2 kg, and more likely to report their health as "good or excellent" (odds ratio (OR) 1.76). They were also less likely to report being a current smoker than EMA negative participants.
The researchers found that EMA positivity was associated with an 8% reduction in mean serum cholesterol, plus reductions in mean hemoglobin, total protein , and corrected serum calcium.
There was also an increased risk of osteoporosis in EMA positive participants (OR 3.1), as well as a risk of mild anemia (OR 4.6), when compared with EMA negative participants.
Dr West's team concluded, "Undetected celiac disease is likely to affect approximately 1% of the population of England aged 45 to 76 years, a value similar to several other countries".
"Those affected report "better health" but they do have an increased risk of osteoporosis and mild anemia".
"In contrast, they have a favorable cardiovascular risk profile that may afford protection from ischemic heart disease and stroke".